KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBIT: 2009-2024

Historic EBIT for Charles River Laboratories International (CRL) over the last 16 years, with Dec 2024 value amounting to $227.3 million.

  • Charles River Laboratories International's EBIT rose 13.96% to $133.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.9 million, marking a year-over-year decrease of 73.31%. This contributed to the annual value of $227.3 million for FY2024, which is 63.17% down from last year.
  • As of FY2024, Charles River Laboratories International's EBIT stood at $227.3 million, which was down 63.17% from $617.3 million recorded in FY2023.
  • In the past 5 years, Charles River Laboratories International's EBIT registered a high of $651.0 million during FY2022, and its lowest value of $227.3 million during FY2024.
  • Moreover, its 3-year median value for EBIT was $617.3 million (2023), whereas its average is $498.5 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 36.31% in 2021, then slumped by 63.17% in 2024.
  • Charles River Laboratories International's EBIT (Yearly) stood at $432.7 million in 2020, then surged by 36.31% to $589.9 million in 2021, then grew by 10.36% to $651.0 million in 2022, then declined by 5.18% to $617.3 million in 2023, then plummeted by 63.17% to $227.3 million in 2024.